AAD 2025: Almirall Presents Early-Stage Pipeline and Real-World Evidence on Tirbanibulin for AK
Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, showcased five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting. These presentations included significant new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and updates on LAD191, a high-affinity monoclonal antibody targeting interleukin-1 receptor accessory protein (IL-1RAP). The data highlights the company’s continued commitment to advancing its early-stage clinical pipeline while offering novel solutions for skin diseases, particularly in dermatology.
Dr. Volker Koscielny, Almirall’s Chief Medical Officer, emphasized the importance of collaboration with the dermatology community and patients. He stated, “Our close collaboration allows us to better understand their needs and develop effective solutions. The findings presented at AAD 2025 focus on delivering impactful data on our established products and advancing our early-stage pipeline. The data on tirbanibulin for the treatment of AK demonstrates the importance of a patient-centered approach to achieve treatment success. Presenting data from the Phase I study of our early-stage asset, LAD191, marks a crucial step toward introducing new treatments to our dermatology portfolio.”
Tirbanibulin Data:
One of the key focuses at AAD 2025 was the presentation of new data on tirbanibulin, which has shown substantial impact on AK treatment success and clearance. The data analyzed tirbanibulin’s efficacy, safety, and tolerability across clinical trials and real-world studies. Notably, the results demonstrate the product’s strong patient satisfaction and the willingness of patients to continue treatment. By combining Phase III, Phase IV, and real-world evidence, these findings underscore the effectiveness of tirbanibulin in addressing AK, an important pre-cancerous skin condition.
Dr. Darrell Rigel, MD, MS, Clinical Professor at Mount Sinai Icahn School of Medicine, emphasized the importance of patient satisfaction in treatment outcomes. He commented, “The results with tirbanibulin indicate notable improvements in patient satisfaction, particularly in real-world settings. This not only supports adherence to AK treatment protocols but also contributes to sustainable outcomes. By prioritizing patient experience and addressing their needs, the effectiveness of therapies can be improved, ultimately enhancing overall care quality.” The analysis highlights the potential for tirbanibulin to achieve long-term success in managing AK while ensuring patient comfort and satisfaction.
LAD191 Data:
In addition to tirbanibulin, Almirall also presented progress on LAD191, a novel, high-affinity monoclonal antibody in development for the treatment of immune-modulated skin diseases, including Hidradenitis Suppurativa (HS). LAD191 works by targeting IL-1RAP, a key receptor in inflammatory pathways. Data from Phase I clinical studies in healthy volunteers provided strong evidence for LAD191’s safety and tolerability. This development builds on previous pre-clinical studies showing that LAD191 inhibits pro-inflammatory cytokines, offering the potential for broader therapeutic benefits.
The mechanism behind LAD191’s action involves blocking multiple pathways associated with IL-1RAP, providing a more comprehensive treatment option compared to targeting a single cytokine. This approach is expected to yield more effective results in reducing inflammatory responses in immune-mediated skin diseases. Almirall’s ongoing work with LAD191 represents a promising future for patients suffering from conditions with limited treatment options.
Addressing Unmet Needs in Medical Dermatology:
Medical dermatology remains an area with substantial unmet needs, as many skin diseases continue to have limited treatment options. Conditions such as psoriasis, atopic dermatitis, and other inflammatory skin diseases significantly impact patients’ physical health, emotional wellbeing, and overall quality of life. As an active participant in AAD 2025, Almirall is committed to fostering collaboration and knowledge exchange in dermatology, aiming to provide transformative solutions that improve patient outcomes.
Almirall’s focus on expanding its portfolio, particularly with biologic treatments for conditions like psoriasis and atopic dermatitis, underscores its commitment to addressing unmet needs in the dermatology space. The company is making continuous strides to advance dermatological treatments through ongoing investment in research and development and partnerships with leading medical and scientific communities.
Almirall’s Commitment to Innovation in Dermatology:
With over 80 years of experience in healthcare, Almirall’s mission is to drive scientific advancements in dermatology. The company remains dedicated to improving the quality of care for patients, with a focus on innovative treatments for dermatological diseases. Their expanding portfolio includes biologic solutions aimed at delivering improved patient outcomes, and the company’s presence at AAD 2025 provided an opportunity to connect with healthcare professionals, industry peers, and partners to share knowledge and expertise.
Almirall’s participation in the AAD 2025 conference reinforced its ongoing dedication to providing cutting-edge treatments that meet patient needs and improve quality of life. The data presented in both tirbanibulin and LAD191 illustrates the company’s vision for the future of dermatology—one that prioritizes patient satisfaction, effective outcomes, and sustainable therapies. Through its continued research and development efforts, Almirall is poised to be a leader in advancing the field of medical dermatology.
